干预前后非小细胞肺癌辅助性用药情况调查与分析  

Investigation and Analysis of Adjunctive Medication for Non-small Cell Lung Cancer before and after Intervention

作　　者：董栋[1] 石祥奎 张居洋[1] 颜海[1] 罗小虎[1] 王健[1] 

机构地区：[1]徐州市肿瘤医院,江苏徐州221000

出　　处：《中国药房》2014年第10期872-874,共3页China Pharmacy

摘　　要：目的:了解临床药师干预前后我院非小细胞肺癌辅助治疗性用药情况,为探讨临床药师参与制订治疗方案及肿瘤多学科综合会诊的合理性提供依据。方法 :对我院2008—2012年病历进行查阅、分析,比较和评价综合规范前后非小细胞肺癌辅助性用药合理性情况。结果:临床药师参与临床后,用药合理性明显提高,降低了不合理的支出,减少了药品不良反应的发生。结论:临床药师应参与非小细胞肺癌的临床治疗工作,从而可增强临床用药合理性。OBJECTIVE： To learn the adjunctive medication for non-small cell lung cancer （NSCLC） in our hospital before and after intervention by clinical pharmacists, and to provide reference for clinical pharmacists participating in the formulation of treatment plan and the rationality of multidisciplinary consultation for the cancer. METHODS ： Medical records of our hospital dur- ing 2008--2012 were reviewed and analyzed, and the rationality of adjunctive medication for NSCLC were compared and evaluat- ed before and after comprehensive intervention. RESULTS： After clinical pharmacists participating in clinical treatment, the rational- ity of drug use was significantly improved and the unreasonable expenditure reduced; the occurrence of ADR was reduced. CONCLUSIONS： Clinical pharmacists should take part in the clinical work about NSCLC. This process can improve the rationality of drug use in the clinic.

关 键 词：非小细胞肺癌 辅助性用药 临床药师 

分 类 号：R969.3[医药卫生—药理学] R734.2[医药卫生—药学]